Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) EBIAT (2016 - 2025)

Historic EBIAT for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$10.6 million.

  • Aytu Biopharma's EBIAT fell 144314.72% to -$10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$25.1 million, marking a year-over-year decrease of 37811.9%. This contributed to the annual value of -$14.2 million for FY2025, which is 1048.98% up from last year.
  • Latest data reveals that Aytu Biopharma reported EBIAT of -$10.6 million as of Q4 2025, which was down 144314.72% from $2.0 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's EBIAT ranged from a high of $4.0 million in Q1 2025 and a low of -$53.3 million during Q1 2022
  • For the 5-year period, Aytu Biopharma's EBIAT averaged around -$10.4 million, with its median value being -$6.9 million (2022).
  • Over the last 5 years, Aytu Biopharma's EBIAT had its largest YoY gain of 23834.43% in 2025, and its largest YoY loss of 144314.72% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's EBIAT stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then skyrocketed by 109.25% to $619000.0 in 2023, then rose by 27.3% to $788000.0 in 2024, then plummeted by 1443.15% to -$10.6 million in 2025.
  • Its EBIAT was -$10.6 million in Q4 2025, compared to $2.0 million in Q3 2025 and -$20.4 million in Q2 2025.